Next Pharmaceuticals

CARLSBAD, Calif.—Next Pharmaceuticals concluded a successful trial of its new patented heart health ingredient, Flavoxine™. After intervention, subjects’ levels of high-density lipoprotein (HDL, or “good”) cholesterol were increased. Flavoxine™ is a blend of two proprietary extracts from Phellodendron amurense and orange peel containing polymethoxylated flavones. Next Pharmaceuticals (www.nextpharmaceuticals.com) said the trial also found Flavoxine significantly lowered blood pressure and fasting blood glucose in the patient population.